Milgamma Na Injekt (Thiamine Hydrochloride, Pyridoxine Hydrochloride)

Thiamine hydrochloride provides vitamin B1, which functions as a co‑enzyme for enzymes like pyruvate dehydrogenase, α‑ketoglutarate dehydrogenase and transketolase. These enzymes are essential for converting carbohydrates into usable energy and for the proper operation of the pentose‑phosphate pathway, thereby supporting cellular metabolism and nervous system health.

The appropriate dose of Milgamma Na Injekt is determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of deficiency, and route of administration. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Data on the use of Milgamma Na Injekt in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Milgamma Na Injekt, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Milgamma Na Injekt uniquely combines thiamine hydrochloride and pyridoxine hydrochloride in a single injectable formulation, targeting both B1 and B6 deficiencies simultaneously. Other vitamin B complex injections may contain additional B‑vitamins or different ratios, which can be advantageous for broader deficiencies but may not provide the focused dosing of B1 and B6 that Milgamma offers.

Milgamma Na Injekt should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Ensure that the cold‑chain is maintained during transport and that the solution is used before the expiration date indicated on the label.

Milgamma Na Injekt is administered by a qualified healthcare professional either intramuscularly or intravenously, depending on the clinical indication and patient needs. The injection should be given slowly, especially for intravenous use, to minimise the risk of hypotension or other infusion‑related reactions.

The most serious risks include severe allergic reactions such as anaphylaxis, sudden hypotension following rapid intravenous administration, and rare neurologic events like seizures. Immediate medical attention is required if any signs of a serious reaction occur, and the product should be discontinued promptly.

Milgamma Na Injekt should be avoided in individuals with known hypersensitivity to thiamine, pyridoxine, or any excipients in the formulation. Patients with uncontrolled severe renal impairment, or those who have experienced previous severe reactions to vitamin B injections, should not receive this product without careful medical evaluation.